兔抗CCNL1多克隆抗體

Background:

Transcriptional regulator which participates in regulating the pre-mRNA splicing process. Seems to be involved in the regulation of RNA polymerase II (pol II). Functions in association with cyclin-dependent kinases (CDKs) and has a role in the second step of splicing. May be a candidate proto-oncogene in head and neck squamous cell carcinomas (HNSCC). Inhibited by the CDK-specific inhibitor p21.

Applications:

WB, IHC

Name of antibody:

CCNL1

Immunogen:

Synthesized peptide derived from human Cyclin-L1.

Full name:

cyclin L1

Synonyms：

ANIA6A; BM-001; PRO1073; ania-6a

SwissProt:

Q9UK58

IHC positive control:

Human breast carcinoma tissue

IHC Recommend dilution:

50-100

WB Predicted band size:

60 kDa

WB Positive control:

HepG2 cells lysate

WB Recommended dilution:

500-3000